UroGen Pharma announced the successful completion of its new drug application, or NDA, submission for investigational drug UGN-102, for intravesical solution. UroGen anticipates potential FDA approval in early 2025, if the NDA is accepted for filing by the FDA and priority review is granted.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Is URGN a Buy, Before Earnings?
- UroGen Pharma Shareholders Shape Governance and Incentives
- UroGen Pharma 5M share Spot Secondary priced at $17.50
- UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
- UroGen Pharma announces offering of ordinary shares, warrants